Metaproterenol Pregnancy and Breastfeeding Warnings
Brand names: Alupent, Metaprel
Medically reviewed by Drugs.com. Last updated on Aug 17, 2023.
Metaproterenol Pregnancy Warnings
Animal studies showed teratogenicity (including skeletal abnormalities, hydrocephalus, and skull bone separation) at 62 times the maximum recommended human dose (MRHD); embryotoxicity was seen at 31 times the MRHD; oral reproduction studies at 40 mg/kg and 50 mg/kg did not show teratogenicity, embryotoxicity, or fetotoxicity. There are no controlled data in human pregnancy.
US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.
This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus.
US FDA pregnancy category: C
Metaproterenol Breastfeeding Warnings
Use is recommended only if the benefit outweighs the risk.
Excreted into human milk: Unknown
Excreted into animal milk: Data not available
See also
References for pregnancy information
- Product Information. Metaproterenol Sulfate (metaproterenol). Par Pharmaceutical Inc. 2022.
References for breastfeeding information
- Product Information. Metaproterenol Sulfate (metaproterenol). Par Pharmaceutical Inc. 2022.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
